Is EW a Buy? What to Consider in 2026
Short answer
The bull case for Edwards Lifesciences (EW) rests on TAVR leadership and label expansion: TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. Total revenue (FY2025) is ~$6.07 billion, up ~11.5%. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Edwards faces several headwinds at once. Whether EW is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Edwards Lifesciences designs and sells devices that treat structural heart disease, conditions where the heart's valves are damaged or diseased. Its largest business is TAVR, a minimally invasive procedure that replaces a narrowed aortic valve with the SAPIEN valve delivered through a catheter rather than open-heart surgery; TAVR generated about $4.49 billion in 2025, roughly three-quarters of company sales. The company also sells transcatheter mitral and tricuspid therapies (TMTT) such as the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral system, plus traditional surgical heart valves and supporting technologies. Edwards makes money by selling these high-margin implantable devices to hospitals worldwide, supported by clinical evidence and physician training that reinforce its leadership. Edwards was spun off from Baxter International in 2000 and became a pure-play structural heart company in 2024 when it divested its Critical Care monitoring business to Becton Dickinson (BD) for roughly $4.2 billion, sharpening its focus on transcatheter heart valves. Recent developments include the EARLY TAVR trial supporting treatment of asymptomatic severe aortic stenosis patients, with Edwards working toward an expanded FDA label, and about $1.2 billion of acquisitions (JenaValve for aortic regurgitation and Endotronix for heart-failure monitoring). TMTT grew more than 56% in 2025 to about $551 million, and the company has returned cash through share buybacks rather than a dividend.
What's the case for buying EW?
1. TAVR leadership and label expansion.
TAVR remains the core franchise, generating about $4.49 billion in 2025, up roughly 9.3% year over year, and Edwards held an estimated low-70s percent share of the U.S. market. The EARLY TAVR trial supports treating asymptomatic severe aortic stenosis patients, and an expanded FDA indication could enlarge the eligible patient pool. Boston Scientific's 2025 exit from TAVR removed one competitor, leaving Medtronic and Abbott as the main rivals.
2. TMTT as the growth engine.
Transcatheter mitral and tricuspid therapies grew about 56% in 2025 to roughly $551 million, driven by the PASCAL repair system, EVOQUE tricuspid valve, and SAPIEN M3 mitral valve. Management guided 2026 TMTT revenue of about $740 to $780 million, implying 35% to 45% growth. This franchise is the clearest path to extending Edwards' structural-heart leadership beyond aortic valves.
3. High margins and strong cash generation.
Edwards runs gross margins near 78%, reflecting the value of differentiated implantable devices and entrenched clinical adoption. That profitability funds heavy R&D and a steady acquisition program. The company returns cash through buybacks, completing a roughly $500 million repurchase in early 2026 with about $1.5 billion remaining under authorization rather than paying a dividend.
4. Pipeline and acquisitions.
Edwards spent about $1.2 billion acquiring JenaValve, which targets aortic regurgitation, and Endotronix, which brings heart-failure monitoring into its ecosystem. These deals expand the addressable market beyond aortic stenosis. Combined with internal programs, they aim to sustain durable growth, though new indications and devices must clear regulatory and reimbursement hurdles before they contribute meaningfully.
What are the risks to EW?
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.
How is EW valued? (as of FY2025 results (year ended December 31, 2025) and early 2026 figures)
- Total revenue (FY2025): ~$6.07 billion, up ~11.5%
- TAVR sales (FY2025): ~$4.49 billion, up ~9.3%
- TMTT growth (FY2025): ~+56%, to ~$551 million
- Adjusted EPS (FY2025): ~$2.56 to $2.62 range
- Gross margin: ~78%
- Market cap: ~$48 to $52 billion
- P/E ratio: ~36x to 49x (varies by basis)
Reading a high-quality medtech like Edwards means weighing durable growth and very high gross margins against a premium valuation. The market has historically paid a P/E well above the broad market for Edwards because of its structural-heart leadership and recurring procedure-driven demand. That premium cuts both ways: when growth stays strong the multiple looks justified, but any deceleration in TAVR or a TMTT stumble can compress the multiple quickly. Because Edwards pays no dividend, total return depends on revenue and earnings growth plus buybacks rather than income.
How do you decide if EW is a buy?
Rather than asking whether EW is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold EW indirectly through an index or sector ETF before adding more.
For the full picture, see the EW stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about EW against your real portfolio and see your actual exposure before deciding.
The bottom line on EW
The bottom line: Edwards Lifesciences's story right now is TAVR leadership and label expansion, with total revenue (fy2025) at ~$6.07 billion, up ~11.5%. If you believe that narrative continues, the call is about sizing EW sensibly and checking overlap with what you own; if you doubt it (the risk: edwards faces several headwinds at once.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around EW with Walnut
Use Edwards Lifesciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is EW a good stock to buy right now?
+
The case for Edwards Lifesciences right now is TAVR leadership and label expansion, with total revenue (fy2025) at ~$6.07 billion, up ~11.5%. If you believe that thesis holds, EW is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is edwards faces several headwinds at once. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Edwards Lifesciences do?
+
The global leader in structural heart disease, best known for its SAPIEN TAVR valves and fast-growing transcatheter mitral and tricuspid therapies.
What are the main risks of EW?
+
Edwards faces several headwinds at once. TAVR growth has decelerated as the aortic-stenosis market matures, and competition from Medtronic's Evolut platform and Abbott's Navitor could erode share even after Boston Scientific's exit. Much of the business depends on favorable reimbursement and FDA decisions, so a delayed or narrowed label expansion (such as for asymptomatic patients) would hurt the growth story. The stock typically trades at a premium multiple, often well above the broad market, which leaves little margin for error if results disappoint. Finally, integrating acquisitions like JenaValve and Endotronix carries execution risk and may pressure near-term margins before the pipeline pays off.
What does Edwards Lifesciences do?
+
Edwards Lifesciences makes devices that treat structural heart disease. Its flagship product is the SAPIEN transcatheter aortic valve, used in TAVR procedures that replace a diseased aortic valve through a catheter instead of open-heart surgery. It also sells transcatheter mitral and tricuspid repair and replacement systems (PASCAL, EVOQUE, SAPIEN M3) and traditional surgical heart valves to hospitals worldwide.
What is TAVR?
+
TAVR stands for transcatheter aortic valve replacement. It is a minimally invasive procedure that replaces a narrowed aortic valve by threading a new valve, such as Edwards' SAPIEN, through a catheter, usually via an artery in the leg, rather than opening the chest. TAVR is Edwards' largest business, generating about $4.49 billion in 2025, and the company is working to expand its use to asymptomatic patients.
Does EW pay a dividend?
+
No. Edwards Lifesciences does not pay a dividend. Instead it returns cash to shareholders through share buybacks, completing a roughly $500 million repurchase in early 2026 with about $1.5 billion remaining under its authorization. The company reinvests heavily in research, development, and acquisitions, so total return for shareholders comes from growth and buybacks rather than dividend income.
How does EW compete with Medtronic?
+
Medtronic is Edwards' closest rival in TAVR through its Evolut/CoreValve platform, which captures a meaningful share of transcatheter aortic valve procedures worldwide. Edwards has historically led the U.S. market with an estimated low-70s percent share, but competition from Medtronic and Abbott's Navitor pressures pricing and share. The two also overlap across the broader structural-heart and cardiovascular device market.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell EW; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.